

To,

Date: 14.11.2022

BSE Limited,
Phiroz Jeejeebhoy Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of the Board meeting held on 14.11.2022

Unit: Decipher Labs Limited (Scrip: 524752)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Decipher Labs Limited held on Monday, 14th November, 2022 at 4.30 p.m. at its registered office at 4th Floor, Plot No. 94, Sagar Society, Banjara Hills, Road No. 2, Hyderabad – 500034 the following were considered and approved/ noted:

1. Un-audited Financial Results (both standalone and consolidated) for the quarter and half year ended 30.09.2022 along with statement of Assets and Liabilities and statement of Cash Flows as on 30.09.2022. **(Enclosed)**
2. Limited Review Report for the quarter ended 30.09.2022. **(Enclosed).**

The meeting concluded at 10:45 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,

For Decipher Labs Limited



Megha Agarwal
Company Secretary and Compliance Officer

Encl: as above

Decipher Labs Limited (CIN CL23230TG1985PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Consolidated Unaudited Financial Results For the Quarter and Half year ended 30 September 2022

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Half Year Ended		Year Ended
	30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	1,212.24	1,261.92	1,492.62	2,474.16	2,832.23	6,532.24
II. Other income	266.03	686.35	9.69	952.38	20.76	767.40
III. Total revenue (I + II)	1,478.27	1,948.27	1,502.31	3,426.54	2,852.99	7,299.64
IV. Expenses						
Purchase of Stock-in-Trade	3.15	31.50	-	34.65	-	15.53
Project Management Cost	-	-	-	-	-	719.17
Employee benefits expense	1,178.20	1,063.18	1,189.33	2,241.38	2,335.77	4,748.68
Finance costs	11.58	11.36	7.66	22.94	20.17	47.66
Depreciation and amortisation expense	10.48	9.76	22.24	20.24	44.47	86.66
Other expenses	117.65	241.48	137.52	359.13	215.22	446.34
Total expenses	1,321.05	1,357.28	1,356.75	2,678.34	2,615.63	6,064.04
V. Profit/(Loss) before tax (III - IV)	157.22	590.99	145.56	748.21	237.36	1,235.60
VI. Tax expense:						
(1) Current tax	37.52	-	51.22	37.52	52.40	170.44
(2) Deferred tax	0.38	0.13	(55.64)	0.51	(31.40)	(73.97)
(3) Tax of earlier years	-	-	0.76	-	0.76	0.75
VII. Profit/(Loss) for the period (V-VI)	119.32	590.86	149.22	710.17	215.60	1,138.38
VIII. Other comprehensive income						
Items that will be reclassified to statement of profit and loss	-	-	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	101.24	57.96	(4.22)	159.20	15.58	56.09
IX. Total comprehensive income for the year	220.56	648.82	145.00	869.37	231.18	1,194.47
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
X. Earning per equity share						
(1) Basic	1.18	5.85	1.48	7.03	21.35	11.27
(2) Diluted	1.18	5.85	1.48	7.03	21.35	11.27

Notes

1. The operations of the Group relate to two segments viz.; Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Half Year Ended		Year Ended
	30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	4.10	45.00	-	49.10	-	68.82
b) Consultancy Services	1,208.15	1,216.92	1,492.62	2,425.07	2,832.23	6,463.42
Total Sales	1,212.24	1,261.92	1,492.62	2,474.16	2,832.23	6,532.24
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	1,212.24	1,261.92	1,492.62	2,474.16	2,832.23	6,532.24
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(6.18)	21.48	-	15.30	-	2.72
b) Consultancy Services	174.97	580.87	165.73	755.84	270.04	255.66
Total	168.79	602.35	165.73	771.14	270.04	258.38
Less: Interest	11.58	11.36	20.17	22.94	32.68	47.66
Total Profit before tax	157.22	590.99	145.56	748.21	237.36	210.72
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	306.53	306.53	276.79	306.53	276.79	261.13
b) Consultancy Services	3,870.71	3,761.04	3,685.86	3,870.71	3,685.86	3,933.17
Total Assets	4,177.24	4,067.57	3,962.65	4,177.24	3,962.65	4,194.30
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	12.24	12.24	21.54	12.24	21.54	8.17
b) Consultancy Services	879.11	990.00	2,341.65	879.11	2,341.65	1,770.21
Total Liabilities	891.35	1,002.24	2,363.19	891.35	2,363.19	1,778.38

2. The above results for the Quarter ended 30 September 2022 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14.11.2022.

3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act')

read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. The above results as of 30.09.2022 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Bahrain.

5. The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

6. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board





Place: Hyderabad
Date: 14.11.2022

Director
DIN: 01227151

Decipher Labs Limited (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Consolidated Statement of Asset and Liabilities as on 30th September,2022

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	As at 30 September 2022 (Unaudited)	As at 31 March 2022 (Audited)
I. ASSETS		
Non-current Assets		
(a) Property, Plant and Equipment	30.54	33.46
(b) Capital work-in-progress	271.30	26.41
(c) Right to use assets	-	-
(d) Deferred tax asset (net)	-	-
(e) Goodwill	250.61	249.24
(f) Financial assets		
Other financial asset	-	62.62
(g) Other non current assets	0.30	0.30
Current Assets		
(a) Inventories	4.42	4.42
(b) Financial assets		
(i) Trade receivables	1,181.00	1,279.21
(ii) Cash and cash equivalents	1,156.96	1,540.86
(iii) Other Financial Asset	1,052.94	768.95
(c) Other current assets	229.20	229.42
TOTAL ASSETS	4,177.24	4,194.90
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	2,275.89	1,406.51
Liabilities		
Non-Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	-	667.39
(ii) Lease Liability	-	-
(b) Deferred tax Liabilities (Net)	0.65	0.14
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	344.39	364.79
(ii) Lease Liability	-	-
(iii) Trade payables		
a) Total outstanding dues of Micro enterprises and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro enterprises and small enterprises	192.42	231.03
(iii) Other Financial liabilities	307.03	381.26
(b) Other current liabilities	0.29	11.05
(c) Current Tax Liabilities (net)	46.58	122.73
TOTAL EQUITY AND LIABILITIES	4,177.23	4,194.90



For and on behalf of the Board

Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 14.11.2022

DECIPHER LABS LIMITED
CONSOLIDATED CASH FLOW STATEMENT AS ON 30 SEPTEMBER 2022

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	30 Sep 2022	31 March 2022
Cash flow from operating activities		
Profit before tax	748.21	1,235.60
Adjustments for :		
Exchange differences on translating the financial statements of a foreign operation	159.20	56.09
Depreciation and amortisation expense	20.24	86.66
Finance costs	22.94	47.66
Pre paid Rent	-	-
Advance to suppliers written off	-	3.05
Balances written back	18.33	(727.24)
Operating Profit before Working Capital Changes		
Changes in operating assets and liabilities		
(Increase) / Decrease in Trade Receivables	79.89	(401.08)
(Increase) / Decrease in Inventories	-	-
(Increase) / Decrease in Other Assets	(221.14)	436.38
Increase / (Decrease) in Trade Payable	(38.61)	116.69
Increase / (Decrease) in Other Liabilities	(217.33)	(27.33)
Cash Generated from Operations	571.73	826.48
Income taxes paid		-
Net cash inflow (outflow) from operating activities	-	826.48
Cash flows from investing activities		
Purchase of Fixed assets including Capital WIP		(19.92)
Investment in shares	(244.89)	(25.41)
Net cash inflow (outflow) from investing activities	(244.89)	(45.33)
Cash flow from financing activities		
Proceeds/(repayment) of borrowings	(687.80)	237.87
Finance costs	(22.94)	(47.66)
Payment for lease liabilities		(60.10)
Net cash inflow (outflow) from financing activities	(710.74)	130.10
Net increase (Decrease) in cash and cash equivalents	(383.90)	911.26
Cash and Cash equivalents at the beginning of the financial Year	1,540.86	697.58
Less: Adjustment on account of cessation of subsidiary company		67.98
Cash and Cash equivalents at the end of the Year	1,156.96	1,540.86

Cash flow statement has been prepared under the indirect method as set out in Ind AS - 7 specified under Section 133 of the Companies Act, 2013.



For and on behalf of the Board

Sushant Mohan Lal
 Director
 DIN: 01227151

Place: Hyderabad
 Date: 14.11.2022

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar Society Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Statement of Standalone Financial Results For the Quarter and Half year Ended 30th September, 2022

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Half Year Ended		Year ended
	30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	12.23	52.90	18.58	65.13	36.93	98.84
II. Other income	1.26	0.58	0.47	1.84	0.93	4.59
III. Total revenue (I + II)	13.50	53.49	19.05	66.97	37.86	103.43
IV. Expenses						
Purchase of Stock in trade	3.15	31.50	-	34.65	-	15.53
Employee benefits expense	4.24	4.05	7.02	8.29	13.76	23.32
Finance Costs	-	-	(0.08)	-	0.02	-
Depreciation expense	1.45	1.47	1.18	2.92	2.35	5.01
Other expenses	6.32	12.01	4.53	18.33	9.73	23.78
Total expenses	15.17	49.02	12.65	64.20	25.86	67.64
V. Profit before tax (III - IV)	(1.67)	4.46	6.40	2.77	12.00	35.79
VI. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	0.38	0.13	0.08	0.51	0.10	(0.25)
VII. Profit/(Loss) for the period (V-VI)	(2.05)	4.33	6.32	2.26	11.90	36.04
VIII. Other comprehensive income	-	-	-	-	-	-
IX. Total comprehensive income for the year	(2.05)	4.33	6.32	2.26	11.90	36.04
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
X. Earning per equity share						
(1) Basic	(0.02)	0.04	0.06	0.02	0.06	0.36
(2) Diluted	(0.02)	0.04	0.06	0.02	0.06	0.36

Notes

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Half Year Ended		Year Ended
	30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	4.10	45.00	-	49.10	-	68.82
b) Consultancy Services	8.14	7.90	18.58	16.04	36.93	30.02
Total Sales	12.23	52.90	18.58	65.13	36.93	98.84
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	12.23	52.90	18.58	65.13	36.93	98.84
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(0.56)	3.80	-	2.09	-	24.92
b) Consultancy Services	(1.11)	0.67	6.32	0.68	12.02	10.87
Total	(1.67)	4.46	6.32	2.77	12.02	35.79
Less: Interest	-	-	(0.08)	-	0.02	-
Total Profit before tax	(1.67)	4.46	6.40	2.77	12.00	35.79
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	1,149.84	1,146.53	276.79	1,149.84	276.79	1,146.31
b) Consultancy Services	20.82	22.47	873.28	20.82	873.28	14.04
Total Assets	1,170.65	1,169.00	1,150.07	1,170.65	1,150.07	1,160.35
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	15.28	12.24	21.54	11.52	21.54	8.04
b) Consultancy Services	-	-	0.51	-	0.51	-
c) Unallocated liabilities	0.94	-	-	-	-	-
Total Liabilities	16.22	12.24	22.05	11.52	22.05	8.04

2. The above results for the quarter ended 30 September 2022 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14.11.2022.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 14.11.2022

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society, Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034

Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Standalone Statement of Assets and Liabilities

Rs. in Lakhs

Particulars	As at	As at
	30 September 2022	31 March 2022
	Unaudited	Audited
I. ASSETS		
Non-current assets		
(a) Property Plant and Equipment	30.53	33.46
(b) Financial assets		
Investments	866.41	866.41
(c) Other non-current assets	0.30	0.30
Current assets		
(a) Inventories	4.42	4.42
(b) Financial assets		
(i) Trade receivables	28.31	21.54
(ii) Cash and cash equivalents	11.43	4.76
(iii) Other financial assets	-	0.55
(c) Current tax assets	0.10	0.06
(d) Other current assets	229.14	228.85
TOTAL ASSETS	1,170.65	1,160.35
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	144.43	142.17
Liabilities		
Non-current liabilities		
(a) Deferred tax liabilities (net)	0.65	0.14
Current Liabilities		
(a) Financial liabilities		
(ii) Trade payables		
a) Total outstanding dues of Micro and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro and small enterprises	3.76	-
(iii) Other financial liabilities	11.52	7.00
(b) Other current liabilities	0.29	1.04
TOTAL EQUITY AND LIABILITIES	1,170.65	1,160.35



For and on behalf of the Board

Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 14.11.2022

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Standalone Statement of Cash Flow for the half year ended 30 September 2022.

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Year ended 30th September, 2022 (Unaudited)		Year ended 31st March, 2022 (Audited)	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		2.77		35.79
Adjustments for :				
Depreciation		2.92		5.01
Advance to suppliers written off		-		3.05
Balances written back		-		(2.14)
Operating Profit before Working Capital Changes		5.70		41.71
Adjustments for:				
(Increase) / Decrease in Trade Receivables	(6.77)		16.83	
(Increase) / Decrease in Other Assets	0.23		(4.38)	
Increase / (Decrease) in Trade Payable	3.76		2.06	
Increase / (Decrease) in Other Liabilities	3.78		(1.44)	
		0.99		13.07
Cash Generated from Operations		6.69		54.78
Direct Taxes Paid		-		-
Net Cash generated from/(used in) Operating Activities		6.69		54.78
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of Property, Plant & Equipment	-		(12.91)	
Investments	-		(25.41)	
Net Cash used in Investing Activities		-		(38.32)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from Short Term Borrowings (net)	-		(13.63)	
Net Cash generated from Financing Activities		-		(13.63)
Net decrease in Cash and Cash Equivalents		6.68		2.83
Cash and Cash Equivalents at the beginning of the year		4.76		1.93
Cash and Cash Equivalents at the end of the period		11.43		4.76

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 14.11.2022



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher labs Limited (Formerly known as Combat Drugs Limited) (the "Company") for the quarter ended 30th September, 2022 and year to date results for the period 1st April, 2022 to 30th September, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)

K.Sreenivasan
Partner
Membership No.206421

UDIN: 22206421BDCUQJ2829
Place : Secunderabad
Date : 14.11.2022





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited (Formerly known as Combat Drugs Limited) ("the Holding Company") and its subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30th September, 2022 and year to date results for the period 1st April, 2022 to 30th September, 2022 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 March 29, 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable
4. The Statement includes the results of the subsidiary Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain.




Ramanatham & Rao

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiaries referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total assets of Rs. 3846.64 Lakhs as at 30th September, 2022, total revenues of Rs. 1212.24 lakhs and Rs. 2474.16 lakhs, total net profit after tax of Rs. 119.32 lakhs and Rs. 710.17 lakhs, total comprehensive Income of Rs. 220.56 lakhs and Rs. 869.37 lakhs for the quarter ended 30th September, 2022 and for the period from 1st April, 2022 to 30th September, 2022 respectively and net cash outflows of Rs. (383.90) Lakhs for the period from 1st April, 2022 to 30th September, 2022 as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of these subsidiaries is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)


K.Sreenivasan
Partner
Membership No.206421

UDIN: 22206421BDCUSG5956
Place : Secunderabad
Date : 14.11.2022

